Exchange Capital Management’s ResMed RMD Stock Holding History

Exchange Capital Management’s Portfolio RMD Stock Details RMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q3	–	Sell	-180	Closed	-$9K	–	244
2014 Q2	$9K	Hold	180	–	–	﹤0.01%	178
2014 Q1	$8K	Hold	180	–	–	﹤0.01%	194
2013 Q4	$8K	Hold	180	–	–	﹤0.01%	165
2013 Q3	$10K	Hold	180	–	–	0.01%	139
2013 Q2	$8K	Buy	+180	New	+$8.54K	﹤0.01%	138

Other funds holding RMD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

CBOA

Commonwealth Bank of Australia Sydney, NSW, Australia $231M AUM

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Exchange Capital Management's RMD Position: Q3 2014 in Review

Exchange Capital Management sold out of ResMed (RMD) in Q3 2014, closing a stake of 180 shares — an estimated $9K sold.

Exchange Capital Management first reported a position in RMD in Q2 2013 and held it in 5 quarters. The position peaked at $10K in Q3 2013. 300 funds tracked by Wall St. Rank hold RMD as of Q3 2014.

Exchange Capital Management reported no remaining ResMed position as of Q3 2014 after selling out during the quarter.
Exchange Capital Management sold 180 ResMed shares in Q3 2014, an estimated $9K.
Exchange Capital Management first reported a position in ResMed in Q2 2013 and held it in 5 quarters.
Exchange Capital Management's ResMed position peaked at $10K in Q3 2013.
300 funds tracked by Wall St. Rank held ResMed as of Q3 2014.

Based on Exchange Capital Management's 13F filing for Q3 2014, filed 3 Oct 2014.